Association between short (≤ 30-day) dual antiplatelet therapy and 1-year major adverse cardiac events after drug-coated balloon-based non-stent percutaneous coronary intervention following optimal lesion preparation: a propensity score-based cohort study
{{output}}
Drug-coated balloon (DCB)-based non-stent percutaneous coronary intervention (PCI) may allow shorter dual antiplatelet therapy (DAPT), but whether a ≤ 30-day regimen is associated with worse outcomes remains unclear, particularly in patients not receiving ora... ...
